Mandate

Vinge is advising Medivir in connection with its rights issue

December 14, 2020 Capital Markets and Public M&A

Vinge is advising Medivir AB (publ) in connection with a rights issue which will provide Medivir with issue proceeds amounting to a maximum of SEK 170 million, as well as with an over-allotment option by way of a directed share issue of a maximum of approximately SEK 25 million.

Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients.

Medivir is listed on Nasdaq Stockholm, Small Cap.

Vinge’s team mainly consisted of Dain Hård Nevonen, Amanda Knutsson, Julia Hirschberg and Olof Löfvenberg.

Related

Vinge advises Intera Partners in connection with the acquisition of Halon Security

Vinge has advised Intera Equity Partners IV Oy (“Intera Partners”) in connection with the acquisition of Halon Security AB (“Halon”).
November 05, 2024

Vinge advises EQT X on its public offer for OEM International

EQT X, through its indirectly owned subsidiary Oak BidCo S.à r.l., has secured an ownership of 72.5% of the votes in OEM International Aktiebolag (publ) and has announced a public cash offer to all shareholders. The shares of OEM International are admitted to trading on Nasdaq Stockholm, Mid Cap. The total value of the offer is approximately SEK 15.2 billion.
November 05, 2024

Vinge advises on the sale of Spring Media to Two Circles

The shareholders of Spring Media have entered into an agreement to sell the shares in Spring Media to Two Circles. Spring Media is an international sports agency operating in, among other things, production, packaging, digital strategies, and rights negotiations in the field of sports rights.
October 28, 2024